Funding for this research was provided by:
GRIFOLS (FACEHBI grant)
ARACLON (FACEHBI grant)
PIRAMAL AG (FACEHBI grant)
Laboratorios ECHEVARNE (FACEHBI grant)
Received: 1 June 2018
Accepted: 29 October 2018
First Online: 29 November 2018
Ethics approval and consent to participate
: The FACEHBI protocol received approval from the ethics review board of the Hospital Clinic i Provincial (Barcelona, Spain) (EudraCT: 2014–000798-38). All the participants signed written informed consent prior to any evaluation according to Spanish biomedical laws and to the principles of the Declaration of Helsinki.
: Not applicable.
: JR, PP, VP-G, and MS are employees of Araclon Biotech Ltd. MS holds several patents related to Alzheimer’s disease diagnosis and treatment, and he is the founder, chief executive officer, chief scientific officer, and one of the current shareholders of Araclon Biotech Ltd. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.